Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma-Reference-Cited by-同舟云学术

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

Published:2020-12-23 Issue:6 Volume:5 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Zhu Qian-Ying¹,Kong Xiang-Wei¹,Sun Cong¹,Xie Shang-Hang²,Hildesheim Allan³,Cao Su-Mei²,Zeng Mu-Sheng¹^ORCID

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China

2. State Key Laboratory of Oncology in South China, Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China

3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA

Abstract

Epstein-Barr virus (EBV) is a human oncogenic gammaherpesvirus that infects over 90% of humans in the world and is causally associated with a spectrum of epithelial and B-cell malignancies such as nasopharyngeal carcinoma (NPC). A prophylactic vaccine against EBV is called for, but no approved vaccine is available yet.

Funder

MOST | National Key Research and Development Program of China

National Natural Science Foundation of China

Guangdong Province Key Research and Development Program

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00901-20

Reference41 articles.

1. Nasopharyngeal carcinoma